Approval · Notice of Compliance 15673 · 2014
RESTASIS: Notice of Compliance 15673
Issued June 2, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15673
- Date
- June 2, 2014
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New drug manufacturing site
- Therapeutic class
- Anti-inflammatory; immunomodulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RESTASIS | Not yet assigned | — |
Medicinal ingredients
- CYCLOSPORINE 0.05 PER